Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Hansoh Pharmaceutical Group Company Limited ( (HK:3692) ) is now available.
Hansoh Pharmaceutical Group Company Limited announced that its self-developed innovative drug, HS-10510 tablets, has received Clinical Trial Approval from China’s National Medical Products Administration. This approval allows the company to proceed with clinical trials targeting primary hypercholesterolemia and mixed dyslipidemia, potentially strengthening its position in the pharmaceutical industry and expanding its product offerings.
The most recent analyst rating on (HK:3692) stock is a Buy with a HK$22.06 price target. To see the full list of analyst forecasts on Hansoh Pharmaceutical Group Company Limited stock, see the HK:3692 Stock Forecast page.
More about Hansoh Pharmaceutical Group Company Limited
Hansoh Pharmaceutical Group Company Limited is a pharmaceutical company incorporated in the Cayman Islands. It focuses on the development of innovative drugs, particularly in the area of hypercholesterolemia and dyslipidemia.
Average Trading Volume: 12,089,628
Technical Sentiment Signal: Buy
Current Market Cap: HK$157.9B
For a thorough assessment of 3692 stock, go to TipRanks’ Stock Analysis page.